RDD Europe 2015 will feature half-day Interactive Workshop Sessions during which the following companies will each sponsor 60-minute presentations (including demonstrations and questions) on new technologies and services related to nasal and pulmonary drug delivery. Focused presentations will be followed by a brief question and answer session. Meeting participants may select and attend up to THREE of these sessions (on the Registration Form) which will be presented on Wednesday, May 6, 2015, from 2:00 to 6:00 PM at the Congress Center.

Please direct any questions or special requests about this event to Claire Jahan.

3M Drug Delivery Systems

Evolving Regulatory Requirements for pMDI Registrations in the US

AstraZeneca

Predicting the Fate of Inhaled Molecules and Applying this Knowledge during Development

FluidDA

Demonstrating the Value of Regional Imaging Biomarkers in Respiratory Drug Development through Functional Respiratory Imaging (FRI)

Gateway Analytical

Assessing Aggregate Performance and the Presence of Foreign Particulate in OINDP's

Harro Höfliger Verpackungsmaschinen

The Challenge of Filling Dry Powder Inhalers including Injection Molded Disks

Hovione

Integrating DPI Development from Inhaler Design to Particle Engineering and Formulation Strategy

International Pharmaceutical Aerosol Consortium on Regulation and Science (IPAC-RS)

Abbreviated Impactor Measurement (AIM) and Effective Data Analysis (EDA) of Aerodynamic Particle Size Data from Orally Inhaled Products (OIP): How to Link with the Product Lifecycle

Nypro Healthcare

Integrating Predictive Design Tools to Achieve a Robust Inhalation Device Design

Proveris Scientific

Application of New Testing Technologies and Methods to Determine Critical Quality Attributes of pMDIs

Qualicaps

Inhaler Device Selection, Comparison of Capsule-based pMDIs and Multi-dose DPIs

rap.ID  Particle Systems

Chemical Identification of Micro Particles from 2 µm and Up: Technology, Application and Validation

Toxikon Europe

Using Leachable Studies to Assist in Establishing an "Organic Impurity Profile" for Inhalation Drug Products